You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR CLOBAZAM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CLOBAZAM

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00162981 ↗ Clobazam in Subjects With Lennox-Gastaut Syndrome Completed Lundbeck LLC Phase 2 2005-10-01 The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in subjects 2 to 30 years of age with Lennox-Gastaut Syndrome (LGS). Subjects will be enrolled at approximately 10 investigational sites in the U.S. for up to 15 weeks. Subjects will be randomly assigned to either a low dose or a high dose. The study will include a baseline period, a titration period and a maintenance period. After the maintenance period, subjects will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.
NCT00518713 ↗ Clobazam in Patients With Lennox-Gastaut Syndrome Completed Lundbeck LLC Phase 3 2007-08-01 The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in patients 2 to 60 years of age with Lennox-Gastaut Syndrome (LGS). Patients will be enrolled at approximately 65 sites in the U.S. and ex-US for up to 23 weeks. Patients will be randomly assigned to either a low, medium or high dose, or placebo. The study will include a baseline period, a titration period and a maintenance period. After the maintenance period, patients will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.
NCT01011036 ↗ Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers Completed University Hospital Inselspital, Berne Phase 3 2009-12-01 The investigators will use an intradermal capsaicin injection in the forearm to induce a state of localized pain. This localized pain will be measured by different means, and analysed locally and distally by so called quantitative sensory testing. The primary endpoint of measure is the difference in pain perception with and without benzodiazepines/GABA-Agonists around the injection point of capsaicin. The secondary endpoints are to measure pain modulation locally and distally by different quantitative tests as electricity, pressure pain thresholds, and ice water tests. The investigators' hypothesis is that clobazam induces higher pain thresholds as placebo and less sedation than the control medication clonazepam.
NCT01160770 ↗ Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome Completed Lundbeck LLC Phase 3 2005-12-01 The objective of this study is to evaluate the long-term safety and effectiveness of open-label clobazam in the treatment of drop seizures in subjects with LGS.
NCT01179828 ↗ Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio) Completed Aalborg University Phase 3 2010-07-01 Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of the classes of pain medication is given to patients with a similar clinical picture, although different pain mechanisms may be responsible for this clinical picture. Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason why an unique drug produces different responses (from a lacking analgesic effect up to excessive effect or side-effects. Quantitative sensory testing is a method that documents alterations in the pain perception system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for anticipation of drug efficacy.
NCT01179828 ↗ Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio) Completed University of Bern Phase 3 2010-07-01 Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of the classes of pain medication is given to patients with a similar clinical picture, although different pain mechanisms may be responsible for this clinical picture. Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason why an unique drug produces different responses (from a lacking analgesic effect up to excessive effect or side-effects. Quantitative sensory testing is a method that documents alterations in the pain perception system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for anticipation of drug efficacy.
NCT01179828 ↗ Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio) Completed University of Zurich Phase 3 2010-07-01 Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of the classes of pain medication is given to patients with a similar clinical picture, although different pain mechanisms may be responsible for this clinical picture. Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason why an unique drug produces different responses (from a lacking analgesic effect up to excessive effect or side-effects. Quantitative sensory testing is a method that documents alterations in the pain perception system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for anticipation of drug efficacy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CLOBAZAM

Condition Name

Condition Name for CLOBAZAM
Intervention Trials
Epilepsy 10
Neuropathic Pain 3
Dravet Syndrome 3
Epilepsy, Generalized 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CLOBAZAM
Intervention Trials
Epilepsy 13
Syndrome 4
Status Epilepticus 3
Seizures 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CLOBAZAM

Trials by Country

Trials by Country for CLOBAZAM
Location Trials
United States 64
India 11
Switzerland 5
United Kingdom 4
Spain 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CLOBAZAM
Location Trials
Texas 5
Massachusetts 5
Florida 5
Maryland 4
Minnesota 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CLOBAZAM

Clinical Trial Phase

Clinical Trial Phase for CLOBAZAM
Clinical Trial Phase Trials
Phase 4 7
Phase 3 10
Phase 2 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CLOBAZAM
Clinical Trial Phase Trials
Completed 12
Terminated 4
Unknown status 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CLOBAZAM

Sponsor Name

Sponsor Name for CLOBAZAM
Sponsor Trials
Lundbeck LLC 5
H. Lundbeck A/S 4
GW Research Ltd 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CLOBAZAM
Sponsor Trials
Other 37
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.